The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients

Gynecologic cancer patients with BSA ≥ 2 m2 treated with WB chemotherapy had no increase in hematologic or non-hematologic toxicities when compared to controls. Consideration should be given to using WB dosing in obese patients with gynecologic malignancies. Further investigation is required to determine the effect of WB dosing on progression-free and overall survival in obese gynecologic cancer patients.